Only One-Quarter of Patients Still Taking Semaglutide for Weight Loss Two Years Later
By Physician’s Briefing Staff HealthDay Reporter
FRIDAY, July 12, 2024 -- Three of four patients stop taking semaglutide (Ozempic or Wegovy) two years after being prescribed the glucagon-like peptide-1 receptor agonist (GLP-1 RA) for weight loss, according to new analysis conducted by Prime Therapeutics and Magellan Rx Management (MRx).
For the review, pharmacy and medical claims data for 3,364 people with insurance plans that cover GLP-1 RAs were examined. Patients had received new prescriptions between January and December 2021, and all were diagnosed with obesity. Importantly, the analysis excluded patients using the drugs for type 2 diabetes, for which GLP-1 RAs were originally developed.
While the report did not delve into why patients quit, it does offer a sobering view of the real-world experiences of people taking the drugs.
With Wegovy, just 24.1 percent of patients stayed on the medication over two years without a gap of 60 days or more, down from 36 percent who stayed on the drug for one year. With Ozempic, which has the same active ingredient as Wegovy, 22.2 percent of patients kept filling their prescriptions at two years, down from 47.1 percent who had used it for one year.
While the new analysis did not ask patients why they stopped using the drugs, it is likely due to a mix of side effects such as nausea and vomiting, out-of-pocket costs not covered by insurance, and supply shortages, analysis coauthor Patrick Gleason, M.D., assistant vice president for health outcomes at Prime/MRx, told Reuters. Some patients may decide to stop the medication once they lose the desired weight, even though research has shown many patients who quit gain the weight back.
"GLP-1s are unlikely to deliver therapeutic value when so many individuals stop treatment after two years, but the findings also illustrate the need for obesity care management programs to improve adherence," David Lassen, chief clinical officer at Prime/MRx, said in a news release.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
Adiposity in Adulthood Linked to Adverse Cardiac Structure, Function
WEDNESDAY, July 17, 2024 -- Higher adiposity over adulthood is associated with adverse cardiac structure and function, according to a study published online July 16 in the...
Obesity Modifies Link Between Birth Weight, Metabolic Phenotypes
TUESDAY, July 16, 2024 -- Associations between lower birth weight (BW) and adverse metabolic phenotypes are more pronounced in children with obesity, according to a study...
Parents' Weight Status at Age 17 Correlates to Offspring Weight at 17
FRIDAY, July 12, 2024 -- The weight status of parents at 17 years of age is associated with obesity risk for both female and male offspring, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.